Amicus Therapeutics filings document the former public company’s rare-disease biotechnology business, common stock registration, operating results, governance matters, shareholder voting disclosures, material agreements, risk factors, clinical or regulatory updates, and capital-structure information. The filing record includes Form 8-K reports for quarterly results, corporate updates, and material events tied to its business and securities.
Later filings document Amicus Therapeutics’ completed merger, its survival as a wholly owned subsidiary of BioMarin Pharmaceutical Inc., the removal of its common stock from Nasdaq listing through Form 25, and the termination or suspension of Exchange Act reporting obligations through Form 15. These documents record the company’s transition from a Nasdaq-listed issuer to a subsidiary within BioMarin.
Barclays PLC reported beneficial ownership of 17,755,672 shares of Amicus Therapeutics Inc common stock, representing 5.65% of the class. The filing shows sole voting power of 17,747,658 shares and shared voting power of 8,014. The report is signed on 05/14/2026.
Amicus Therapeutics ownership disclosure: The filing reports that The Goldman Sachs Group, Inc. and affiliate Goldman Sachs & Co. LLC together hold 16,782,162.81 shares of Amicus common stock, representing 5.3% of the class, with shared voting and shared dispositive power reported.
The filing is a joint Schedule 13G statement executed by GS Group and Goldman Sachs & Co. LLC and includes exhibits identifying the reporting subsidiary relationship and a joint filing agreement.
Amicus Therapeutics reports that UBS Group and its subsidiaries beneficially own 17,141,817 shares of Common Stock, representing 5.46% of the class. The filing states UBS Group AG filed on behalf of UBS Financial Services Inc., UBS Securities LLC, UBS AG London Branch and UBS Switzerland AG. The filer reports shared voting power of 17,071,007 shares and shared dispositive power of 14,222,423.
Amicus Therapeutics, Inc. received a Schedule 13G filing from Glazer Capital, LLC and Paul J. Glazer identifying themselves as former large holders. The filing states the Reporting Persons currently beneficially own 0 shares of Amicus common stock (CUSIP 03152W109) representing 0% of the class.
The statement notes the Reporting Persons "have ceased to be the beneficial owner of more than five percent of the class of securities." The filing lists the Reporting Persons' business address and is signed by Paul J. Glazer on 05/01/2026.